Real-World Outcomes and Digitally Monitored Quality of Life in Crizanlizumab-Treated Patients With Sickle Cell Disease | Sanius Health

2dia-circ

SICKLE CELL DISEASE

Real-World Outcomes and Digitally Monitored Quality of Life in Crizanlizumab-Treated Patients With Sickle Cell Disease

European Haematology Association (2023)

Areas of interest /
Outcomes research & novel therapeutic impacts

Biomarkers /
EQ-5D-5L, Side Effects, Disease Symptoms

Published in /
HemaSphere, European Haematology Association

Contact

< Back to Sanius content

Real-World-Outcomes-and-Digitally-Monitored-Quality-of-Life-in-Crizanlizumab-Treated-Patients-With-Sickle-Cell-Disease-